Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3201)
All Articles published online
|
Publishing Process of This Article
|
Mar 16, 2022 (publication date) through May 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Liu LF, Deng JY, Lizaso A, Lin J, Sun S. Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report. World J Clin Cases 2022; 10(8): 2529-2536 [PMID: 35434049 DOI: 10.12998/wjcc.v10.i8.2529] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i8/2529.htm |
| Number | Citing Articles |
| 1 |
|
| 2 |
Dantong Sun, Weizheng Wu, Li Wang, Jialin Qu, Qiman Han, Huiyun Wang, Shanai Song, Ning Liu, Yongjie Wang, Helei Hou. Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer. Journal of Translational Medicine 2023; 21(1) doi: 10.1186/s12967-023-03999-7
|
| 3 |
Su-Su Dong, Wen Dong, Ya-Fen Tan, Qiang Xiao, Tian-Li Wang. Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and KIF5B-MET fusion. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1370901
|
| 4 |
Dantong Sun, Xiaoming Xing, Yongjie Wang, Helei Hou. MET fusions are targetable genomic variants in the treatment of advanced malignancies. Cell Communication and Signaling 2024; 22(1) doi: 10.1186/s12964-023-01454-0
|
| 5 |
Jaclyn LoPiccolo, Alexander Gusev, David C. Christiani, Pasi A. Jänne. Lung cancer in patients who have never smoked — an emerging disease. Nature Reviews Clinical Oncology 2024; 21(2): 121 doi: 10.1038/s41571-023-00844-0
|